61 results
6-K
EX-10.1
PRTG
Portage Biotech Inc
3 Oct 23
Current report (foreign)
4:05pm
U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).
(ll) U.S. Real Property Holding
424B5
PRTG
Portage Biotech Inc
2 Oct 23
Prospectus supplement for primary offering
6:01pm
of leading, world class universities and institutes, such as the Department of Investigative Medicine at University of Oxford, The National Cancer
6-K
EX-2.1
dq5ujj6
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
EX-2.1
malctg4x 679
8 Jul 22
Current report (foreign)
8:58am
6-K
EX-10.3
jf2oefu
8 Jul 22
Current report (foreign)
8:58am
SUPPL
kxwcz5gk
24 Jun 21
Supplemental materials (foreign)
5:27pm
6-K
EX-99.1
pbdh339z0dyd5r3
24 Jun 21
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
4:05pm
6-K
EX-99.2
7633m5z3t9121y5ev2h
24 Jun 21
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
4:05pm
6-K
EX-1.1
f84ibpci6
24 Jun 21
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
4:05pm
SUPPL
fwbyv0uggitnj qoj4
23 Jun 21
Supplemental materials (foreign)
4:01pm
424B2
bm4d6hh2tyx43
8 Mar 21
Prospectus for primary offering
5:00pm
F-3
EX-1.1
4pxobg2 njs9fou
24 Feb 21
Shelf registration (foreign)
5:22pm
F-3
6dwrq1t
24 Feb 21
Shelf registration (foreign)
5:22pm